<DOC>
	<DOCNO>NCT01961531</DOCNO>
	<brief_summary>To evaluate safety 5 fraction accelerate partial brest irradiation convenient 5 fraction schedule .</brief_summary>
	<brief_title>BrUOG 291 : Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy ( NIBB )</brief_title>
	<detailed_description>The purpose study evaluate rate early intermediate toxicity relate accelerate partial breast irradiation ( APBI ) deliver convenient 5 fraction schedule use non-invasive image-guided breast brachytherapy ( NIBB ) ( AccuBoost System ) woman resect , early stage breast cancer . Non-invasive image-guided breast brachytherapy ( NIBB ) , use advanced image-guided radiation technology , potential eliminate disadvantage conventional APBI technique . NIBB facilitate non-invasive partial breast irradiation without use catheter implant . Yet use breast immobilization precise image-guidance , reduce non-target breast tissue within irradiated field compare non-invasive APBI technique 3D-CRT . This make NIBB attractive approach deliver APBI . We hypothesize NIBB deliver 5 treatment convenient , safe effective modality deliver partial breast irradiation . Anticipated advantage NIBB protocol treatment include : - Convenient treatment schedule - Short course allow increase patient access treatment - Non-invasive approach - Increased accuracy precise target lumpectomy cavity use advanced image - Reduced irradiation non-target breast tissue - Reduced skin toxicity - No heart lung radiation exposure - Reduced late skin breast toxicity - High rate good excellent cosmetic outcome - High rate ipsilateral breast tumor control comparable APBI technique</detailed_description>
	<criteria>1 . A confirmed histological diagnosis invasive breast carcinoma DCIS ; 2 . Age great equal 50 year old ; 3 . Life expectancy &gt; 6 month ; 4 . Treated breast conserve surgery 5 . Pathologic lymph node negative , include ( pN0 , i+ ) ; Patients , low risk sentinel node involvement sentinel node biopsy perform , eligible treat investigator document clinically lymph node negative ( cN0 ) . These patient include : DCIS Microinvasion Pure tubular mucinous histology Patients â‰¥ 70yo T1aT1c ; estrogen receptor + 6 . Pathologic tumor size 1. less equal 2 cm invasive disease ; 2. less equal 3 cm DCIS ; 7 . Estrogen receptor positive invasive disease ( DCIS ER negative ) 8 . Negative surgical margin great equal 2 mm . A margin &lt; 2mm acceptable natural boundary , i.e . skin pectoralis fascia . 9 . No lymphovascular invasion ; 10 . ECOG performance status 02 ( Appendix 1 ) ; 11 . Informed consent sign . 1 . Known BRCA 1/2 Mutation ; ( BRCA 1 2 testing require ) 2 . Active lupus scleraderma ; 3 . Pregnancy ; 4 . Psychiatric addictive disorder would preclude attend followup ; 5 . Neoadjuvant chemotherapy ( adjuvant chemotherapy permit ) ; 6 . Suspicious remain microcalcification postsurgery mammogram ( unless biopsy proven benign ) ; 7. pN+ axillary dissection sentinel lymph node biopsy ( N0i+ consider node negative exclude ) ; 8 . Multicentric disease ; 9 . Paget 's disease nipple ; 10 . Breast Implants 11 . Distant metastasis ; 12 . Lumpectomy cavity well visualize AccuBoost imaging ; 13 . Lumpectomy cavity 1cm margin ( CTV/PTV ) adequately encompass available applicator . 14 . Breast separation compression &gt; 8cm time simulation .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>DCIS</keyword>
	<keyword>IDC</keyword>
	<keyword>Invasive breast carcinoma</keyword>
</DOC>